Ascendis Pharma A/S Files 20-F for FY2024

Ticker: ASND · Form: 20-F · Filed: Feb 12, 2025 · CIK: 1612042

Sentiment: neutral

Topics: 20-F, annual-report, pharmaceutical

TL;DR

Ascendis Pharma A/S dropped its 2024 20-F. Check financials.

AI Summary

Ascendis Pharma A/S filed its 20-F for the fiscal year ending December 31, 2024. The filing, submitted on February 12, 2025, provides a comprehensive overview of the company's operations and financial standing. Key financial data and operational details for the period are included, with specific references to entities like Ascendis Pharma Sverige Ab and Ascendis Pharma Growth Disorders AS.

Why It Matters

This filing provides investors and stakeholders with the official annual financial and operational report for Ascendis Pharma A/S, crucial for understanding the company's performance and future outlook.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Ascendis Pharma A/S is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Ascendis Pharma A/S?

Ascendis Pharma A/S is in the business of Pharmaceutical Preparations, as indicated by its SIC code [2834].

When was the 20-F filing submitted?

The 20-F filing was submitted on February 12, 2025.

What is the fiscal year end for Ascendis Pharma A/S?

The fiscal year end for Ascendis Pharma A/S is December 31.

Which subsidiaries of Ascendis Pharma A/S are mentioned in the filing data?

Ascendis Pharma Sverige Ab and Ascendis Pharma Growth Disorders AS are mentioned.

Who is the auditor for Ascendis Pharma A/S?

The auditor is Deloitte Statsautoriseret Revisionspartnerselskab.

Filing Stats: 4,397 words · 18 min read · ~15 pages · Grade level 18.1 · Accepted 2025-02-12 16:15:38

Filing Documents

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 178 Item 12

Description of Securities Other than Equity Securities

Description of Securities Other than Equity Securities 178 PART II 180 Item 13 Defaults, Dividend Arrearages and Delinquencies 180 Item 14 Material Modification to the Rights of Security Holders and Use of Proceeds 180 Item 15

Controls and Procedures

Controls and Procedures 180 Item 16A Audit Committee Financial Expert 181 Item 16B Code of Ethics 181 Item 16C Principal Accountant Fees and Services 181 Item 16D Exemptions from the Listing Standards for Audit Committees 182 Item 16E Purchases of Equity Securities by the Issuer and Affiliated Purchasers 182 Item 16F Change in Registrant's Certifying Accountant 182 Item 16G Corporate Governance 182 Item 16H Mine Safety Disclosure 183 Item 16I Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 183 Item 16J Insider Trading Policies 183 Item 16K Cybersecurity 183 PART III 186 Item 17

Financial Statements

Financial Statements 186 Item 18

Financial Statements

Financial Statements 186 Item 19 Exhibits II- 1 Gen eral As used herein, references to "we", "us", the "company", "Ascendis", or "Ascendis Pharma", or similar terms in this annual report on Form 20-F shall mean Ascendis Pharma A/S and, as the context requires, its subsidiaries. Our consolidated financial statements are presented in euros except where otherwise indicated, and are prepared in accordance with IFRS Accounting Standards ("IFRS"), as issued by the International Accounting Standards Board. All references in this annual report to "Dollars", "USD" and "$" are to U.S. Dollars, and all references to "euro", "EUR" or "" are to European Union euro. Throughout this annual report, references to ADSs mean ADSs or ordinary shares represented by ADSs, as the case may be. Special Note Regarding Forward-Looking Statements This annual report contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would," and other similar expressions that are predictions or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: the timing or likelihood of regulatory filings and approvals for our product candidates; our expectations regarding the commercial availability of our approved products; the commercialization of our products

Identity of Directors, Senior Management and Advisers

Item 1 Identity of Directors, Senior Management and Advisers Not applicable.

Offer Statistics and Expected Timetable

Item 2 Offer Statistics and Expected Timetable Not applicable.

Key Information

Item 3 Key Information A. Reserved B. Capitalization and Indebtedness Not applicable. C. Reasons for the Offer and Use of Proceeds Not applicable. D. Risk Factors Our business faces significant risks. You should carefully consider all of the information set forth in this annual report and in our other filings with the SEC, including the following risk factors which we face and which are faced by our industry. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. This annual report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this annual report and our other materials we file or furnish with the SEC. See "Special Note Regarding Forward-Looking Statements" above. Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements We have a limited operating history and we may incur significant losses in the future, which makes it difficult to assess our future viability. We are applying our innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by our core values of patients, science, and passion, we use our TransCon technologies to create new and potentially best-in-class therapies. We currently have a pipeline of multiple independent endocrinology rare disease, and oncology candidates in development. We are also working to apply our TransCon technology platform in additional therapeutic areas to address unmet medical needs. On August 25, 2021, the FDA approved TransCon hGH, known by its brand name SKYTROFA and its international nonproprietary name lonapegsomatropin-tcgd in the U.S. for the treatment of pediatric patients one year and older

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing